Corvus Pharmaceuticals, Inc.

CRVS · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$62-$27-$41-$43
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$3$2$3$4
Change in WC-$2-$4$1-$3
Other Non-Cash$35$4$10$5
Operating Cash Flow-$25-$24-$27-$37
Investing Activities
PP&E Inv.$0-$0-$0-$0
Net Acquisitions$0$0$0-$0
Inv. Purchases-$70-$47-$66-$9
Inv. Sales/Matur.$43$63$43$31
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$27$16-$23$22
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$16$8$0$61
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$33$0$0$1
Financing Cash Flow$49$8$0$62
Forex Effect$0$0$0$0
Net Chg. in Cash-$4-$1-$50$47
Supplemental Information
Beg. Cash$13$13$63$16
End Cash$9$13$13$63
Free Cash Flow-$25-$24-$27-$37